Initial study results show that people lose a larger percentage of weight as much as 30% of their body weight when they take retatrutide compared with placebo
A: While there have been initial concerns, large randomized trials have not proven a causal link between GLP-1 agonists and conditions like pancreatitis or pancreatic cancer
Studies consistently show that even moderate weight loss, around 10% of body weight, can have meaningful benefits for sexual performance and overall sexual health
Brown used the sabbatical to develop a RIA for GIP
Lawyers handling GLP-1 litigation often work with physicians, economic experts, and other specialists to assess the full financial and personal impact of an injury, including future medical needs and long-term disability
Mounjaro Mounjaro represents the next generation of weight loss medication